Identification of Clinically Significant Prostate Cancer by Combined PCA3 and AMACR mRNA Detection in Urine Samples.
Elena S KotovaYulia A SavochkinaYurii Valerievich DoludinAlexander O VasilyevElena A PrilepskayNatalia V PotoldykovaKonstantin A BabalyanAlexandra V KanyginaAndrey O MorozovAlexander V GovorovDmitry V EnikeevElena S KostryukovaElena N IlinaVadim M GovorunDmitry Y PushkarElena I SharovaPublished in: Research and reports in urology (2020)
The AMACR score is a good predictor of clinically significant prostate cancer. Significant amounts of nonprostate RNA in urine may be a limitation for the AMACR score use. Evaluation of the AMACR score and classification models based on it for clinically significant prostate cancer detection with larger samples and a follow-up analysis is promising.